Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it ...

Myriad Genetics was issued, five laboratories announced they would begin offering BRCA testing to patients. In an attempt to hold on to its monopoly, Myriad took legal action against some, but not all ...

Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing. The biotech company, the subject of a 2013 Supreme Court ruling that genes cannot be patented, said it was giving up trying to ...

Myriad Genetics, Inc. SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that ...

There's been a major selloff in Myriad Genetics, Inc. (NASDAQ:MYGN) shares in the week since it released its first-quarter report, with the stock down 42% to US$4.27. Myriad Genetics' revenues ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by.

Myriad Genetics beat analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $213.3 million, up 11.2% year on year. It was a very strong quarter for the company, ...

Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing.

Debt Management: Myriad Genetics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.2. This indicates a heavier reliance on borrowed funds, ...

Lu Li, an analyst from UBS, has initiated a new Hold rating on Myriad Genetics (MYGN). Pick the best stocks and maximize your portfolio: Lu Li has given his Hold rating due to a combination of ...

Genetic-testing firm Myriad Genetics is facing a legal challenge from people who say the company refused to give them access to their own genomic data, in violation of a US government rule on ...

In a report released yesterday, Rachel Vatnsdal from J.P. Morgan maintained a Sell rating on Myriad Genetics (MYGN – Research Report), with a price target of $20.00. Rachel Vatnsdal’s rating ...